Organogenesis Holdings reported a net loss of $96.3 million for the second quarter of 2026, compared to a net loss of $9.4 million in the same period last year. Net revenue fell 58% to $42.8 million, driven by a 61% decline in Advanced Wound Care product revenue to $36.1 million, while Surgical & Sports Medicine revenue decreased 18% to $6.7 million. The company also lowered its full-year 2026 revenue guidance to between $179 million and $215 million, representing a decline of 62% to 68% from 2025. Adjusted EBITDA loss widened to $34.4 million from $3.6 million a year earlier. Cash and equivalents stood at $46.8 million with no outstanding debt as of June 30, 2026.
Organogenesis Holdings IncReports large net loss, revenue decline, and lowered guidance.
